样式: 排序: IF: - GO 导出 标记为已读
-
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-16 Frederick M. Lang, Sergio Teruya, Ariel Weinsaft, Margaret Cuomo, Alfonsina Mirabal Santos, Ani Nalbandian, Dimitrios Bampatsias, Mathew S. Maurer
AimsDespite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short‐term efficacy and safety of SGLT2i in ATTR‐CM.Methods and resultsWe screened consecutive patients seen at a tertiary care
-
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-15 Alexander Peikert, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai, Pardeep S. Jhund, Jaclyn Carberry, Carolyn S.P. Lam, Mikhail N. Kosiborod, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
-
Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-14 Christian Gerges, Karl Vollmers, Nika Skoro‐Sajer, Varius Dannenberg, Valerie Hartig, Marc R. Pritzker, John Scandurra, E. Kenneth Weir, Irene M. Lang
-
The salt paradox in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Zachary L. Cox, Jeffrey M. Testani
-
Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Nathanael Wood, Sam Straw, Chew W. Cheng, Yu Hirata, Marcelo G. Pereira, Harrison Gallagher, Stuart Egginton, Wataru Ogawa, Stephen B. Wheatcroft, Klaus K. Witte, Lee D. Roberts, T. Scott Bowen
-
Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-11 Karl‐Patrik Kresoja, Sebastian Rosch, Anne Rebecca Schöber, Karl Fengler, Florian Schlotter, Sara Bombace, Paula Sagmeister, Maximilian von Roeder, Tobias Kister, Matthias Gutberlet, Holger Thiele, Karl‐Philipp Rommel, Philipp Lurz
AimsThe aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge‐to‐edge repair (T‐TEER) as a model of right ventricular (RV) volume overload relief.Methods and resultsThis prospective interventional single arm trial (NCT04782908) included patients
-
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 Justin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, Piotr Ponikowski, Carolyn S.P. Lam, Christopher M. O'Connor, Javed Butler, Stefano Corda, Ciaran J. McMullan, Cynthia M. Westerhout, Adriaan A. Voors, Robert J. Mentz, Paul W. Armstrong
-
Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge‐to‐edge repair Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-08 Tetsu Tanaka, Atsushi Sugiura, Refik Kavsur, Can Öztürk, Nihal Wilde, Sebastian Zimmer, Georg Nickenig, Marcel Weber, Johanna Vogelhuber
-
Weight telemonitoring of heart failure versus standard of care in a real‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 François Roubille, Grégoire Mercier, Guila Lancman, Hélène Pasche, Sarah Alami, Cécile Delval, Antoine Bessou, Jade Vadel, Amayelle Rey, Stéphanie Duret, Emilie Abraham, Gilles Chatellier, Isabelle Durand Zaleski
-
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-06 Matteo Pagnesi, Oscar Alberto Gomez Vilamajó, Alejandro Meiriño, Carlos Alberto Dumont, Alexandre Mebazaa, Beth Davison, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Celutkiene, Kamilė Čerlinskaitė‐Bajorė, Ovidiu Chioncel, Alain Cohen‐Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam, Maria Novosadova
AimsA high‐intensity care (HIC) strategy with rapid guideline‐directed medical therapy (GDMT) up‐titration and close follow‐up visits improved outcomes, compared to usual care (UC), in patients recently hospitalized for acute heart failure (AHF). Hypotension is a major limitation to GDMT implementation. We aimed to assess the impact of baseline systolic blood pressure (SBP) on the effects of HIC versus
-
‘Micro’‐managing heart failure: Restoring that which was lost in translation Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 A. Mark Richards, Peipei Wang, Lee Lee Wong
-
Iron replacement therapy in heart failure: Contextualizing the results of the HEART‐FID trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Javed Butler, Robert J. Mentz, Adrian F. Hernandez
-
Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Zainali S. Chunawala, Neil Keshvani, Matthew W. Segar, Kershaw V. Patel, Muhammad Shariq Usman, Vinayak Subramanian, Viraj Raygor, Alvin Chandra, Muhammad Shahzeb Khan, Ambarish Pandey
-
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Stuart J. Pocock, Stefan D. Anker, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Faiez Zannad, James L. Januzzi
-
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Martha Grogan, Margot K. Davis, Maria G. Crespo‐Leiro, Marla B. Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna
AimsTo evaluate the effect of long‐term tafamidis treatment on health‐related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension (LTE) study.Methods and resultsWe examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ‐OS)
-
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Faiez Zannad, Milton Packer, Gerasimos Filippatos, Stuart J. Pocock, Francisco Vasques‐Nóvoa, Michael Böhm, Javed Butler, Stefan Anker
-
Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Hans L.A. Nienhuis, Peter van der Meer
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized fatal disease characterized by extracellular deposition of misfolded transthyretin proteins causing heart failure (HF).1 Previous studies on ATTR-CM prevalence have mostly been performed retrospectively and in selected cohorts.2-4 A recent community screening study found that ATTR-CM, defined in this study by a Perugini grade ≥2 out
-
An exercise enigma: Unravelling the complexity of exercise intolerance in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-28 Matthew W. Segar, Ajith Nair, Ambarish Pandey
-
Apoptosis, a useful marker in the management of hot‐phase cardiomyopathy? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-28 Giulia Bassetto, Marco Merlo, Matteo Dal Ferro, Martina Setti, Alessia Paldino, Chiara Collesi, Rebecca Artioli, Francesco Loffredo, Saverio D'Elia, Paolo Golino, Enrico Fabris, Rossana Bussani, Marco Metra, Giuseppe Limongelli, Gianfranco Sinagra
-
Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-26 Martina Setti, Marco Merlo, Marta Gigli, Laura Munaretto, Alessia Paldino, Davide Stolfo, Carola Pio Loco, Kristen Medo, Caterina Gregorio, Antonio De Luca, Sharon Graw, Matteo Castrichini, Antonio Cannatà, Flavio Luciano Ribichini, Matteo Dal Ferro, Matthew Taylor, Gianfranco Sinagra, Luisa Mestroni
-
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-26 Michele D'Alto, Marco Di Maio, Paola Argiento, Emanuele Romeo, Gaetano Rea, Biagio Liccardo, Carmen Del Giudice, Andrea Vergara, Eleonora Caiazza, Gerardo Elia Del Vecchio, Alessandro Di Vilio, Luna Gargani, Antonello D'Andrea, Eduardo Bossone, Paolo Golino, Eugenio Picano, Robert Naeije
-
Correction to ‘Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-20
Núñez, J, Espriella, R, Rossignol, P, Voors, AA, Mullens, W, Metra, M, et al. Congestion in heart failure: A circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur J Heart Fail 2022; 24: 1751–1766. https://doi.org/10.1002/ejhf.2664 The title of the above paper was incorrect in the originally published
-
Use of natriuretic peptides and echocardiography for diagnosing heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-20 Khawaja M. Talha, James L. Januzzi, Tong Meng, Stephen J. Greene, Muthiah Vaduganathan, Tijana K. Janicijevic, Ani John, Antoni Bayes-Genis, Javed Butler
-
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-23 Mauro Riccardi, Matteo Pagnesi, Ovidiu Chioncel, Alexandre Mebazaa, Gad Cotter, Finn Gustafsson, Daniela Tomasoni, Nicola Latronico, Marianna Adamo, Marco Metra
Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi‐organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two
-
New opportunity for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-23 Bertram Pitt, Sai Prasad N. Iyer, H. David Humes
Introduction Despite current therapy of patients hospitalized with acute (AHF) or worsening (WHF) heart failure, both heart failure with a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF), there remains a relatively high incidence of cardiovascular (CV) mortality and hospitalizations for HF (HHF) at 30 and 90 days post-admission and/or discharge.1 The administration of sodium–glucose
-
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. Insights from the ESC-EORP Valvular Heart Disease II survey Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-19 Julien Dreyfus, Monika Komar, David Attias, Michele De Bonis, Frank Ruschitzka, Bogdan A. Popescu, Cécile Laroche, Christophe Tribouilloy, Alexander Bogachev Prokophiev, Vaida Mizariene, Jeroen J. Bax, Aldo Pietro Maggioni, David Messika-Zeitoun, Alec Vahanian, Bernard Iung
-
Early left ventricular unloading via active transseptal left atrial venting in case of cardiogenic shock under veno‐arterial extracorporeal membrane oxygenation: A meta‐analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-20 Aurore Ughetto, Safa Aouinti, Nicolas Molinari, François Roubille, Clément Delmas
While veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as mechanical circulatory support for cardiogenic shock (CS) refractory to medical treatment, recent randomized controlled trials have all failed to demonstrate any benefit in terms of 30-day survival compared with optimal medical treatment in CS related to myocardial infarction.1 These disappointing results may
-
All roads lead to… myocardial ischaemia in cardiac amyloidosis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-19 Laurenz Hauptmann, Christian Nitsche
-
-
Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-19 Masatoshi Minamisawa, Riccardo M. Inciardi, Brian Claggett, Maja Cikes, Li Liu, Narayana Prasad, Tor Biering‐Sørensen, Carolyn S.P. Lam, Sanjiv J. Shah, Michael R. Zile, Eileen O'Meara, Margaret M. Redfield, John J.V. McMurray, Scott D. Solomon, Amil M. Shah
-
Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among community-dwelling adults without cardiovascular disease: The Dallas Heart Study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-12 Vinayak Subramanian, Neil Keshvani, Matthew W. Segar, Nitin J. Kondamudi, Alvin Chandra, Bhumika Maddineni, Susan A. Matulevicius, Erin D. Michos, Joao A.C. Lima, Jarett D. Berry, Ambarish Pandey
-
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-06 Pablo Garcia-Pavia, Martha Grogan, Parag Kale, John L. Berk, Mathew S. Maurer, Isabel Conceição, Marcelo Di Carli, Scott D. Solomon, Chongshu Chen, Elena Yureneva, John Vest, Julian D. Gillmore
-
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-04 Bart J. van Essen, Ganash N. Tharshana, Wouter Ouwerkerk, Poh Suan Daniel Yeo, David Sim, Fazlur Jaufeerally, Hean Yee Ong, Lieng Hsi Ling, Dinna Kar Nee Soon, Shao Guang Sheldon Lee, Gerard Leong, Seet Yoong Loh, Ru San Tan, Chrishan J. Ramachandra, Derek J. Hausenloy, Oi Wai Liew, Jenny Chong, Adriaan A. Voors, Carolyn S.P. Lam, A. Mark Richards, Jasper Tromp
-
Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) randomized controlled trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-02-01 Tauben Averbuch, Shun Fu Lee, Brandon Zagorski, Alexandre Mebazaa, Gregg C. Fonarow, Lehana Thabane, Harriette G.C. Van Spall
-
Association between secondhand smoke exposure and incident heart failure: The Multi-Ethnic Study of Atherosclerosis (MESA) Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-30 Gen-Min Lin, Donald M. Lloyd-Jones, Laura A. Colangelo, Joao A.C. Lima, Moyses Szklo, Kiang Liu
There are no studies on the association between secondhand smoke (SHS) exposure and incident heart failure (HF). This cohort study aimed to examine the associations of self-reported and urinary cotinine-assessed SHS exposure with incident HF.
-
Transcatheter aortic valve replacement in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-31 Puja B. Parikh, Michael Mack, Gregg W. Stone, Stefan D. Anker, Ian C. Gilchrist, Andreas P. Kalogeropoulos, Milton Packer, Hal A. Skopicki, Javed Butler
-
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-25 Johann Bauersachs, Scott D. Solomon, Stefan D. Anker, Isabel Antorrena-Miranda, Sandor Batkai, Janika Viereck, Steffen Rump, Gerasimos Filippatos, Ulrich Granzer, Piotr Ponikowski, Rudolf A. de Boer, Orly Vardeny, Wilfried Hauke, Thomas Thum
-
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-25 Wilfried Mullens, Jeroen Dauw, Finn Gustafsson, Alexandre Mebazaa, Jan Steffel, Klaus K. Witte, Victoria Delgado, Cecilia Linde, Kevin Vernooy, Stefan D. Anker, Ovidiu Chioncel, Davor Milicic, Gerd Hasenfuß, Piotr Ponikowski, Ralph Stephan von Bardeleben, Friedrich Koehler, Frank Ruschitzka, Kevin Damman, Ehud Schwammenthal, Jeffrey M. Testani, Faiez Zannad, Michael Böhm, Martin R. Cowie, Kenneth Dickstein
Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have
-
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-21 Tripti Rastogi, João Pedro Ferreira, Javed Butler, Bettina Johanna Kraus, Michaela Mattheus, Martina Brueckmann, Gerasimos Filippatos, Christoph Wanner, Stuart J. Pocock, Milton Packer, Stefan D. Anker, Faiez Zannad
-
Neuromodulation interventions in the management of heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-21 Amr Abdin, Lucas Lauder, Marat Fudim, William T. Abraham, Stefan D. Anker, Michael Böhm, Felix Mahfoud
Despite remarkable improvements in the management of heart failure (HF), HF remains one of the most rapidly growing cardiovascular condition resulting in a substantial burden on healthcare systems worldwide. In clinical practice, however, a relevant proportion of patients are treated with suboptimal combinations and doses lower than those recommended in the current guidelines. Against this background
-
Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-21 Jeroen Dauw, Evelyne Meekers, Pieter Martens, Sébastien Deferm, Sebastiaan Dhont, Wouter Marchal, Liesbeth Mesotten, Matthias Dupont, Petra Nijst, W.H. Wilson Tang, Stefan P. Janssens, Wilfried Mullens
-
Myocardial perfusion in cardiac amyloidosis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-21 Liza Chacko, Tushar Kotecha, Adam Ioannou, Niket Patel, Ana Martinez-Naharro, Yousuf Razvi, Rishi Patel, Paolo Massa, Lucia Venneri, James Brown, Aldostefano Porcari, Kristopher Knott, Charlotte Manisty, Daniel Knight, Tim Lockie, Roby Rakhit, Helen Lachmann, Ashutosh Wechelakar, Carol Whelan, Markella Ponticos, James Moon, Arantxa González, Janet Gilbertson, Mattia Riefolo, Ornella Leone, Hui Xue
-
Myocardial sodium–glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-21 Lucia Scisciola, Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Leen Delrue, Fatemeh Taktaz, Rosaria Anna Fontanella, Ivan Degrieck, Ada Pesapane, Filip Casselman, Armando Puocci, Martina Franzese, Frank Van Praet, Michele Torella, Raffaele Marfella, Marisa De Feo, Jozef Bartunek, Giuseppe Paolisso, Emanuele Barbato, Michelangela Barbieri, Marc Vanderheyden
-
The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-18 Muhammad Shariq Usman, James L. Januzzi, Stefan D. Anker, Ali Salman, Puja B. Parikh, Marianno Adamo, Gerasimos Filippatos, Muhammad Shahzeb Khan, Anuradha Lala, Subodh Verma, Marco Metra, Javed Butler
-
Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-12 Samuel Seidu, Claire A. Lawson, Setor K. Kunutsor, Kamlesh Khunti, Giuseppe M.C. Rosano
-
Corrigendum to ‘Congestion in heart failure: A circulating biomarker-based perspective’ and articles listed below Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-11
Massimo Piepoli's affiliations were incorrect. It should have read: Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Clinical Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. The affected articles are listed in the reference list. We apologize for these errors.
-
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-01-03 Theresa A. McDonagh, Marco Metra, Marianna Adamo, Roy S. Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel, John G.F. Cleland, Maria Generosa Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W. Hoes, Tiny Jaarsma, Ewa A. Jankowska, Mitja Lainscak, Carolyn S.P. Lam, Alexander R. Lyon, John J.V. McMurray, Alexandre Mebazaa,
Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Elisabetta Cerbai (Italy), Erwan Donal (France), Frank Edelmann (Germany), Gloria Färber (Germany), Bettina Heidecker (Germany), Borja
-
Clinical phenogroup diversity and multiplicity: impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-29 Kathryn Larson, Massar Omar, Hidemi Sorimachi, Kazunori Omote, Alessio Alogna, Dejana Popovic, Atsushi Tada, Shunichi Doi, Jwan Naser, Yogesh N.V. Reddy, Margaret M. Redfield, Barry A. Borlaug
-
Cardiorespiratory fitness and risk of heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-28 Peter Kokkinos, Charles Faselis, Andreas Pittaras, Immanuel Babu Henry Samuel, Carl J. Lavie, Jose D. Vargas, Michael Lamonte, Barry Franklin, Themistocles L. Assimes, Rayelynn Murphy, Jiajia Zhang, Xuemei Sui, Jonathan Myers
Preventive strategies for heart failure with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. However, the association between cardiorespiratory fitness (CRF) assessed objectively by a standardized exercise treadmill test (ETT) and the risk of HFpEF has not been evaluated. Thus, we evaluated the association between CRF and HFpEF incidence.
-
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-28 Jack Wu, Dhruva Biswas, Matthew Ryan, Brett M. Bernstein, Maleeha Rizvi, Natalie Fairhurst, George Kaye, Ranu Baral, Tom Searle, Narbeh Melikian, Daniel Sado, Thomas F. Lüscher, Richard Grocott-Mason, Gerald Carr-White, James Teo, Richard Dobson, Daniel I. Bromage, Theresa A. McDonagh, Ajay M. Shah, Kevin O'Gallagher
-
Exercise catheterization in adults post-Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-28 William R. Miranda, C. Charles Jain, Barry A. Borlaug, Heidi M. Connolly, Luke J. Burchill, Alexander Van De Bruaene, Alexander C. Egbe
-
The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-22 Daniela Tomasoni, Cristiana Vitale, Federica Guidetti, Lina Benson, Frieder Braunschweig, Ulf Dahlström, Michael Melin, Giuseppe M.C. Rosano, Lars H. Lund, Marco Metra, Gianluigi Savarese
-
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61 Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-22 Siddharth M. Patel, David A. Morrow, Andrea Bellavia, David D. Berg, Deepak L. Bhatt, Petr Jarolim, Lawrence A. Leiter, Darren K. McGuire, Itamar Raz, P. Gabriel Steg, John P.H. Wilding, Marc S. Sabatine, Stephen D. Wiviott, Eugene Braunwald, Benjamin M. Scirica, Erin A. Bohula
N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure risk remains incompletely defined.
-
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-22 Edoardo Bertero, Chiara Chiti, Maria Alessandra Schiavo, Giacomo Tini, Paolo Costa, Giancarlo Todiere, Barbara Mabritto, Lorenzo-Lupo Dei, Alessia Giannattasio, Davide Mariani, Carla Lofiego, Caterina Santolamazza, Emanuele Monda, Giovanni Quarta, Davide Barbisan, Giulia Elena Mandoli, Massimo Mapelli, Maurizio Sguazzotti, Francesco Negri, Simona De Vecchi, Michele Ciabatti, Daniela Tomasoni, Andrea
In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real-world HOCM patients with those enrolled in EXPLORER-HCM and assessing their eligibility to treatment.
-
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-22 Marianna Adamo, Ovidiu Chioncel, Matteo Pagnesi, Antoni Bayes-Genis, Magdy Abdelhamid, Stefan D. Anker, Elena-Laura Antohi, Luigi Badano, Tuvia Ben Gal, Michael Böhm, Victoria Delgado, Julien Dreyfus, Francesco F. Faletra, Dimitrios Farmakis, Gerasimos Filippatos, Julia Grapsa, Finn Gustafsson, Jörg Hausleiter, Tiny Jaarsma, Nicole Karam, Lars Lund, Philipp Lurz, Francesco Maisano, Brenda Moura, Wilfred
Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. While medical therapy for right-sided heart failure is limited, treatment options for tricuspid regurgitation include surgery and, based on recent developments, several transcatheter interventions. However, the patients
-
Effective medications can work only in patients who take them: Implications for post-acute heart failure care Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-20 Gad Cotter, Beth A. Davison, Kirkwood F. Adams, Andrew P. Ambrosy, Lina Atabaeva, Craig J. Beavers, Ankeet S. Bhatt, Michael M. Givertz, Justin L. Grodin, Anuradha Lala, Mikhail Novosadov, George G. Sokos, Koji Takagi, John R. Teerlink, Deepak L. Bhatt
Acute heart failure (AHF) remains a predominant cause of hospitalization, especially among individuals aged 65 years or older, contributing to millions of hospitalizations per year globally.1, 2 Despite advances in therapeutic approach, AHF remains a syndrome with a poor prognosis, in-hospital mortality rates of 4% to 7% globally, and readmission rates ranging from 22% to 30% at 6 months.3 Guideline-directed
-
Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-20 W.H. Wilson Tang, Ina Nemet, Xinmin S. Li, Yuping Wu, Arash Haghikia, Marco Witkowski, Robert A. Koeth, Ilja Demuth, Maximilian König, Elisabeth Steinhagen-Thiessen, Fredrik Bäckhed, Michael A. Fischbach, Arjun Deb, Ulf Landmesser, Stanley L. Hazen
-
Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-20 Rafael de la Espriella, Kramer J. Wahlberg, Margaret Infeld, Patricia Palau, Eduardo Núñez, Juan Sanchis, Markus Meyer, Julio Núñez
-
Independent prognostic importance of blood urea nitrogen to creatinine ratio in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-20 Paolo Tolomeo, Jawad H. Butt, Toru Kondo, Gianluca Campo, Akshay S. Desai, Pardeep S. Jhund, Lars Køber, Martin P. Lefkowitz, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Muthiah Vaduganathan, Michael R. Zile, Milton Packer, John J.V. McMurray
-
Impact of anaemia and iron deficiency on outcomes in cardiogenic shock complicating acute myocardial infarction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-12-12 Danilo Obradovic, Goran Loncar, Uwe Zeymer, Janine Pöss, Hans-Josef Feistritzer, Anne Freund, Alexander Jobs, Georg Fuernau, Steffen Desch, Uta Ceglarek, Berend Isermann, Stephan von Haehling, Stefan D. Anker, Petra Büttner, Holger Thiele